SCHEMBL6474786

SCHEMBL6474786

COc1ccc(-c2ccc(COCCc3cccc(NS(=O)(=O)C(F)(F)F)c3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
CYP19A1 P11511 1/20 0.40
ERBB2 P04626 1/20 0.40
ERBB4 Q15303 1/20 0.40
KDM1A O60341 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PTGS1 P23219 3/20 0.39
PTGS2 P35354 3/20 0.39
CA2 P00918 1/20 0.39
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
MMP12 P39900 2/20 0.39
PPARA Q07869 1/20 0.39
CYSLTR2 Q9NS75 1/20 0.39
CYSLTR1 Q9Y271 1/20 0.39
PTPN1 P18031 1/20 0.38
PRMT6 Q96LA8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479426 0.94 KDM1A (0.43) LTB4RSLC22A12CYP19A1KDM1APTGS1
SCHEMBL6482071 0.90 FFAR1 (0.43) LTB4RSLC22A12CYP19A1ERBB2ERBB4
SCHEMBL6482076 0.88 KDM1A (0.38) LTB4RSLC22A12CYP19A1ERBB2ERBB4
SCHEMBL6479679 0.88 KDM1A (0.42) ERBB2ERBB4KDM1APTGS1PTGS2
SCHEMBL6483863 0.87 PPARA (0.47) CYP19A1KDM1APTGS1PTGS2CA2
SCHEMBL6482520 0.87 KIF11 (0.46) ERBB2ERBB4KDM1ACA2PPARA
SCHEMBL6474092 0.85 PPARA (0.41) ERBB2ERBB4KDM1APTGS1PTGS2
SCHEMBL6475739 0.85 PTPN1 (0.48) PTGS1PTGS2CA2CYSLTR2CYSLTR1
SCHEMBL6474743 0.85 TP53 (0.44) LTB4RTDP1L3MBTL1
SCHEMBL6482194 0.84 KDM1A (0.43) KDM1APTGS1PTGS2CA2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 LTB4R 3476/4885TDP1 4018/4885L3MBTL1 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.